



97TH GENERAL ASSEMBLY

State of Illinois

2011 and 2012

HB1825

by Rep. Ann Williams

SYNOPSIS AS INTRODUCED:

215 ILCS 5/356z.19 new

Amends the Illinois Insurance Code. Provides that accident and health insurance policies that provide coverage for prescribed orally-administered cancer medications and intravenously administered or injected cancer medications shall ensure that the applicable financial requirements and treatment limitations are no more restrictive than the financial requirements and treatment limitations applied to intravenously administered or injected cancer medications that are covered by the policy. Provides that an insurer cannot achieve compliance with the coverage mandate by increasing financial requirements or imposing more restrictive treatment limitations on prescribed orally-administered cancer medications or intravenously administered or injected cancer medications covered under the policy. Effective immediately.

LRB097 05082 RPM 45123 b

1 AN ACT concerning insurance.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Insurance Code is amended by adding
5 Section 356z.19 as follows:

6 (215 ILCS 5/356z.19 new)

7 Sec. 356z.19. Cancer drug parity.

8 (a) As used in this Section:

9 "Financial requirement" means deductibles, copayments,
10 coinsurance, out-of-pocket expenses, aggregate lifetime
11 limits, and annual limits.

12 "Treatment limitation" means limits on the frequency of
13 treatment, days of coverage, or other similar limits on the
14 scope or duration of treatment.

15 (b) On and after the effective date of this amendatory Act
16 of the 97th General Assembly, every insurer that amends,
17 delivers, issues, or renews an individual or group policy of
18 accident and health insurance amended, delivered, issued, or
19 renewed on or after the effective date of this amendatory Act
20 of the 97th General Assembly that provides coverage for
21 prescribed orally-administered cancer medications and
22 intravenously administered or injected cancer medications
23 shall ensure that:

1 (1) the financial requirements applicable to such
2 prescribed orally-administered cancer medications are no
3 more restrictive than the financial requirements applied
4 to intravenously administered or injected cancer
5 medications that are covered by the policy and that there
6 are no separate cost-sharing requirements that are
7 applicable only with respect to such prescribed
8 orally-administered cancer medications; and

9 (2) the treatment limitations applicable to such
10 prescribed orally-administered cancer medications are no
11 more restrictive than the treatment limitations applied to
12 intravenously administered or injected cancer medications
13 that are covered by the policy and that there are no
14 separate treatment limitations that are applicable only
15 with respect to such prescribed orally-administered cancer
16 medications.

17 (c) An insurer cannot achieve compliance with this Section
18 by increasing financial requirements or imposing more
19 restrictive treatment limitations on prescribed
20 orally-administered cancer medications or intravenously
21 administered or injected cancer medications covered under the
22 policy on the effective date of this amendatory Act of the 97th
23 General Assembly.

24 Section 99. Effective date. This Act takes effect upon
25 becoming law.